Trial · NCT01196416
Results by group19
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 19 of 19
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Objective Response | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Partial Response (PR) | 3 | Participants | |
| Overall Objective Response | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Stable Disease (SD) | 3 | Participants | |
| Overall Objective Response | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Progression of Disease (POD) | 6 | Participants | |
| Maximum-tolerated Dose for Cisplatin, Vinblastine and TMZ | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Cisplatin | 20 | mg/m2 | |
| Maximum-tolerated Dose for Cisplatin, Vinblastine and TMZ | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Vinblastine | 1.2 | mg/m2 | |
| Maximum-tolerated Dose for Cisplatin, Vinblastine and TMZ | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Temozolomide | 150 | mg/m2 | |
| Overall Survival (Phase II) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Partial Response | 3 | participants | |
| Overall Survival (Phase II) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Stable Disease | 5 | participants | |
| Overall Survival (Phase II) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Progression of Disease | 6 | participants | |
| Maximum Tolerated Dose for RO4929097 | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | 15 | mg/day | ||
| Participants' Change in Protein Levels | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | decrease in post-treatment cleaved notch protein | 4 | Participants | |
| Participants' Change in Protein Levels | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | no change | 1 | Participants | |
| Cycle 1 AUC/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | 5410 | Standard Deviation 3355 | hr·ng/mL | |
| Cycle 1 C Max/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | 301 | Standard Deviation 172 | ng/mL | |
| Cycle 1 Mean Day 2 Trough/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | 129 | Standard Deviation 88 | ng/mL | |
| Number of Participants With Presence or Absence of Markers of Notch Signalling Pathway Inhibition in Patient Tumors (Phase Ib) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Insufficient tissue to asses any change | 1 | Participants | |
| Number of Participants With Presence or Absence of Markers of Notch Signalling Pathway Inhibition in Patient Tumors (Phase Ib) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | Sig decrease in post-treatment cleaved Notch | 4 | Participants | |
| Progression-free Survival (Phase II) | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | 2.7 | Full Range 1.2 to 4.1 | months | |
| Participants Evaluated for Toxicity | Treatment (RO4929097, Cisplatin, Vinblastine, Temozolomide) | 14 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01196416/results